These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 27705940)

  • 1. Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.
    Richard NP; Pippa R; Cleary MM; Puri A; Tibbitts D; Mahmood S; Christensen DJ; Jeng S; McWeeney S; Look AT; Chang BH; Tyner JW; Vitek MP; Odero MD; Sears R; Agarwal A
    Oncotarget; 2016 Dec; 7(51):84214-84227. PubMed ID: 27705940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.
    Agarwal A; MacKenzie RJ; Pippa R; Eide CA; Oddo J; Tyner JW; Sears R; Vitek MP; Odero MD; Christensen DJ; Druker BJ
    Clin Cancer Res; 2014 Apr; 20(8):2092-103. PubMed ID: 24436473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer.
    Farrell AS; Allen-Petersen B; Daniel CJ; Wang X; Wang Z; Rodriguez S; Impey S; Oddo J; Vitek MP; Lopez C; Christensen DJ; Sheppard B; Sears RC
    Mol Cancer Res; 2014 Jun; 12(6):924-39. PubMed ID: 24667985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.
    Janghorban M; Farrell AS; Allen-Petersen BL; Pelz C; Daniel CJ; Oddo J; Langer EM; Christensen DJ; Sears RC
    Proc Natl Acad Sci U S A; 2014 Jun; 111(25):9157-62. PubMed ID: 24927563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma.
    Enjoji S; Yabe R; Fujiwara N; Tsuji S; Vitek MP; Mizuno T; Nakagawa T; Usui T; Ohama T; Sato K
    J Vet Med Sci; 2015 Nov; 77(11):1451-6. PubMed ID: 26062569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The concept of the okadaic acid class of tumor promoters is revived in endogenous protein inhibitors of protein phosphatase 2A, SET and CIP2A, in human cancers.
    Fujiki H; Sueoka E; Watanabe T; Suganuma M
    J Cancer Res Clin Oncol; 2018 Dec; 144(12):2339-2349. PubMed ID: 30341686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer.
    Cristóbal I; Caramés C; Rincón R; Manso R; Madoz-Gúrpide J; Torrejón B; González-Alonso P; Rojo F; García-Foncillas J
    Oncotarget; 2017 Jun; 8(25):40169-40180. PubMed ID: 27517624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
    Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
    Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.
    Saddoughi SA; Gencer S; Peterson YK; Ward KE; Mukhopadhyay A; Oaks J; Bielawski J; Szulc ZM; Thomas RJ; Selvam SP; Senkal CE; Garrett-Mayer E; De Palma RM; Fedarovich D; Liu A; Habib AA; Stahelin RV; Perrotti D; Ogretmen B
    EMBO Mol Med; 2013 Jan; 5(1):105-21. PubMed ID: 23180565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.
    Hu X; Garcia C; Fazli L; Gleave M; Vitek MP; Jansen M; Christensen D; Mulholland DJ
    Sci Rep; 2015 Nov; 5():15182. PubMed ID: 26563471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A.
    Hung MH; Wang CY; Chen YL; Chu PY; Hsiao YJ; Tai WT; Chao TT; Yu HC; Shiau CW; Chen KF
    Oncotarget; 2016 Jan; 7(1):638-55. PubMed ID: 26575017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A potential therapeutic application of SET/I2PP2A inhibitor OP449 for canine T-cell lymphoma.
    Fujiwara N; Kawasaki H; Yabe R; Christensen DJ; Vitek MP; Mizuno T; Sato K; Ohama T
    J Vet Med Sci; 2013; 75(3):349-54. PubMed ID: 23131782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
    Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
    Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PP2A inhibitor SET promotes mTORC1 and Bmi1 signaling through Akt activation and maintains the colony-formation ability of cancer cells.
    Kohyanagi N; Kitamura N; Ikeda S; Shibutani S; Sato K; Ohama T
    J Biol Chem; 2024 Jan; 300(1):105584. PubMed ID: 38141761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell acute lymphoblastic leukemia associated with complex karyotype and SET-NUP214 rearrangement: a case study and review of the literature.
    Lee SG; Park TS; Cho SY; Lim G; Park GJ; Oh SH; Cho EH; Chong SY; Huh JY
    Ann Clin Lab Sci; 2011; 41(3):267-72. PubMed ID: 22075511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stemness Is Enhanced in Gastric Cancer by a SET/PP2A/E2F1 Axis.
    Enjoji S; Yabe R; Tsuji S; Yoshimura K; Kawasaki H; Sakurai M; Sakai Y; Takenouchi H; Yoshino S; Hazama S; Nagano H; Oshima H; Oshima M; Vitek MP; Matsuura T; Hippo Y; Usui T; Ohama T; Sato K
    Mol Cancer Res; 2018 Mar; 16(3):554-563. PubMed ID: 29330298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.
    Cristóbal I; Manso R; Rincón R; Caramés C; Senin C; Borrero A; Martínez-Useros J; Rodriguez M; Zazo S; Aguilera O; Madoz-Gúrpide J; Rojo F; García-Foncillas J
    Mol Cancer Ther; 2014 Apr; 13(4):938-47. PubMed ID: 24448818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic targeting of CHK1 and mTOR in MYC-driven tumors.
    Song X; Wang L; Wang T; Hu J; Wang J; Tu R; Su H; Jiang J; Qing G; Liu H
    Carcinogenesis; 2021 Apr; 42(3):448-460. PubMed ID: 33206174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis.
    Lim JT; Singh N; Leuvano LA; Calvert VS; Petricoin EF; Teachey DT; Lock RB; Padi M; Kraft AS; Padi SKR
    Mol Cancer Ther; 2020 Sep; 19(9):1809-1821. PubMed ID: 32753387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A.
    Christensen DJ; Ohkubo N; Oddo J; Van Kanegan MJ; Neil J; Li F; Colton CA; Vitek MP
    J Immunol; 2011 Feb; 186(4):2535-42. PubMed ID: 21289314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.